Profile | GDS2987 / GI_10835094-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 0.3 | 1 |
GSM215244 | HMVEC_vehicle_rep2 | 9.4 | 24 |
GSM215253 | HMVEC_vehicle_rep3 | 7.7 | 26 |
GSM215254 | HMVEC_atorvastatin_rep1 | 23.9 | 52 |
GSM215282 | HMVEC_atorvastatin_rep3 | 10.9 | 25 |
GSM215344 | HMVEC_atorvastatin_rep2 | 11.1 | 28 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 15.4 | 29 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 10 | 17 |
GSM215294 | HMVEC_SLx2119_rep1 | 13.2 | 43 |
GSM215295 | HMVEC_SLx2119_rep2 | 39.2 | 59 |
GSM215296 | HMVEC_SLx2119_rep3 | 28.5 | 44 |
GSM215297 | PASMC_vehicle_rep1 | 16.4 | 25 |
GSM215298 | PASMC_vehicle_rep2 | 50.7 | 60 |
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | 19.8 | 33 |
GSM215312 | PASMC_atorvastatin_rep2 | 60 | 65 |
GSM215313 | PASMC_atorvastatin_rep3 | 54 | 61 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | ||
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 58.5 | 67 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 53.8 | 64 |
GSM215327 | PASMC_SLx2119_rep1 | 40.1 | 56 |
GSM215328 | PASMC_SLx2119_rep2 | 25.4 | 42 |
GSM215329 | PASMC_SLx2119_rep3 | 16.7 | 31 |
GSM215330 | Fibroblasts_vehicle_rep1 | 12.9 | 30 |
GSM215331 | Fibroblasts_vehicle_rep2 | 15 | 39 |
GSM215332 | Fibroblasts_vehicle_rep3 | 25.7 | 59 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 12 | 31 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 15.8 | 41 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 7.2 | 18 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 18.8 | 51 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 13 | 39 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 11.9 | 32 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 26.5 | 58 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 10.2 | 28 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 16.4 | 39 |